These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 30588188)

  • 21. Bone morphogenetic protein-9 is a potent growth inhibitor of hepatocellular carcinoma and reduces the liver cancer stem cells population.
    Jung JW; Yoon SM; Kim S; Jeon YH; Yoon BH; Yang SG; Kim MK; Choe S; Kuo MM
    Oncotarget; 2016 Nov; 7(45):73754-73768. PubMed ID: 27650540
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interferon-β gene-modified human bone marrow mesenchymal stem cells attenuate hepatocellular carcinoma through inhibiting AKT/FOXO3a pathway.
    Xie C; Xie DY; Lin BL; Zhang GL; Wang PP; Peng L; Gao ZL
    Br J Cancer; 2013 Sep; 109(5):1198-205. PubMed ID: 23887606
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Both antiangiogenesis- and angiogenesis-independent effects are responsible for hepatocellular carcinoma growth arrest by tyrosine kinase inhibitor PTK787/ZK222584.
    Liu Y; Poon RT; Li Q; Kok TW; Lau C; Fan ST
    Cancer Res; 2005 May; 65(9):3691-9. PubMed ID: 15867364
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nogo-B receptor promotes the chemoresistance of human hepatocellular carcinoma via the ubiquitination of p53 protein.
    Dong C; Zhao B; Long F; Liu Y; Liu Z; Li S; Yang X; Sun D; Wang H; Liu Q; Liang R; Li Y; Gao Z; Shao S; Miao QR; Wang L
    Oncotarget; 2016 Feb; 7(8):8850-65. PubMed ID: 26840457
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Sustained clinical response of large hepatocellular carcinoma after chemoembolization with pirarubicin, amiodarone and Lipiodol].
    Cercueil JP; Ferrant E; Isambert N; Jouve JL; Flesch M; Krause D; Bedenne L; Chauffert B
    Gastroenterol Clin Biol; 2004 Dec; 28(12):1281-3. PubMed ID: 15671939
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MEL-pep, an analog of melittin, disrupts cell membranes and reverses 5-fluorouracil resistance in human hepatocellular carcinoma cells.
    Ke M; Dong J; Wang Y; Zhang J; Zhang M; Wu Z; Lv Y; Wu R
    Int J Biochem Cell Biol; 2018 Aug; 101():39-48. PubMed ID: 29800725
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of mTOR as a primary resistance factor of the IAP antagonist AT406 in hepatocellular carcinoma cells.
    Zhen MC; Wang FQ; Wu SF; Zhao YL; Liu PG; Yin ZY
    Oncotarget; 2017 Feb; 8(6):9466-9475. PubMed ID: 28036295
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway.
    He C; Dong X; Zhai B; Jiang X; Dong D; Li B; Jiang H; Xu S; Sun X
    Oncotarget; 2015 Oct; 6(30):28867-81. PubMed ID: 26311740
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dual targeting of mTORC1/C2 complexes enhances histone deacetylase inhibitor-mediated anti-tumor efficacy in primary HCC cancer in vitro and in vivo.
    Shao H; Gao C; Tang H; Zhang H; Roberts LR; Hylander BL; Repasky EA; Ma WW; Qiu J; Adjei AA; Dy GK; Yu C
    J Hepatol; 2012 Jan; 56(1):176-83. PubMed ID: 21835141
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MK2206 overcomes the resistance of human liver cancer stem cells to sorafenib by inhibition of pAkt and upregulation of pERK.
    Zhai B; Zhang X; Sun B; Cao L; Zhao L; Li J; Ge N; Chen L; Qian H; Yin Z
    Tumour Biol; 2016 Jun; 37(6):8047-55. PubMed ID: 26711788
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anti-tumour effects of PIM kinase inhibition on progression and chemoresistance of hepatocellular carcinoma.
    Leung MS; Chan KK; Dai WJ; Wong CY; Au KY; Wong PY; Wong CC; Lee TK; Ng IO; Kao WJ; Lo RC
    J Pathol; 2020 Sep; 252(1):65-76. PubMed ID: 32558942
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Salinomycin decreases doxorubicin resistance in hepatocellular carcinoma cells by inhibiting the β-catenin/TCF complex association via FOXO3a activation.
    Zhou Y; Liang C; Xue F; Chen W; Zhi X; Feng X; Bai X; Liang T
    Oncotarget; 2015 Apr; 6(12):10350-65. PubMed ID: 25871400
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preclinical evaluation of combined TKI-258 and RAD001 in hepatocellular carcinoma.
    Chan SL; Wong CH; Lau CP; Zhou Q; Hui CW; Lui VW; Ma BB; Chan AT; Yeo W
    Cancer Chemother Pharmacol; 2013 Jun; 71(6):1417-25. PubMed ID: 23546591
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Overexpression of Protein Phosphatase 1γ (PP1γ) Is Associated with Enhanced Cell Proliferation and Poor Prognosis in Hepatocellular Carcinoma.
    Li C; Wu M; Zong G; Wan C; Liu Q; Zhou H; Hua L; Chen Y; Chen X; Lu C
    Dig Dis Sci; 2017 Jan; 62(1):133-142. PubMed ID: 27921263
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Knockdown of RIPK1 Markedly Exacerbates Murine Immune-Mediated Liver Injury through Massive Apoptosis of Hepatocytes, Independent of Necroptosis and Inhibition of NF-κB.
    Suda J; Dara L; Yang L; Aghajan M; Song Y; Kaplowitz N; Liu ZX
    J Immunol; 2016 Oct; 197(8):3120-3129. PubMed ID: 27605011
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Water extract of Hedyotis Diffusa Willd suppresses proliferation of human HepG2 cells and potentiates the anticancer efficacy of low-dose 5-fluorouracil by inhibiting the CDK2-E2F1 pathway.
    Chen XZ; Cao ZY; Chen TS; Zhang YQ; Liu ZZ; Su YT; Liao LM; Du J
    Oncol Rep; 2012 Aug; 28(2):742-8. PubMed ID: 22641337
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hepatocyte-specific TAK1 deficiency drives RIPK1 kinase-dependent inflammation to promote liver fibrosis and hepatocellular carcinoma.
    Tan S; Zhao J; Sun Z; Cao S; Niu K; Zhong Y; Wang H; Shi L; Pan H; Hu J; Qian L; Liu N; Yuan J
    Proc Natl Acad Sci U S A; 2020 Jun; 117(25):14231-14242. PubMed ID: 32513687
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expression of PTEN, p27, p21 and AKT mRNA and protein in human BEL-7402 hepatocarcinoma cells in transplanted tumors of nude mice treated with the tripeptide tyroservatide (YSV).
    Zhu Z; Jia J; Lu R; Lu Y; Fu Z; Zhao L; Wang L; Jin M; Zhao L; Gao W; Yao Z
    Int J Cancer; 2006 Mar; 118(6):1539-44. PubMed ID: 16184552
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of PI3K/mTOR inhibition in combination with sorafenib in hepatocellular carcinoma treatment.
    Gedaly R; Angulo P; Chen C; Creasy KT; Spear BT; Hundley J; Daily MF; Shah M; Evers BM
    Anticancer Res; 2012 Jul; 32(7):2531-6. PubMed ID: 22753710
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Regulation of Akt/FoxO3a/Skp2 Axis Is Critically Involved in Berberine-Induced Cell Cycle Arrest in Hepatocellular Carcinoma Cells.
    Li F; Dong X; Lin P; Jiang J
    Int J Mol Sci; 2018 Jan; 19(2):. PubMed ID: 29360760
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.